Tumor Metabolome Targeting and Drug Development

Steven Kanner

ISBN 10: 146149544X / ISBN 13: 9781461495444

Published by Springer, 2014

About this Item

Tumor Metabolome Targeting and Drug Development | Steven Kanner | Buch | Cancer Drug Discovery and Development | viii | Englisch | 2014 | Springer | EAN 9781461495444 | Verantwortliche Person für die EU: Springer Verlag GmbH, Tiergartenstr. 17, 69121 Heidelberg, juergen[dot]hartmann[at]springer[dot]com | Anbieter: preigu Print on Demand.

Seller Inventory # 105639192

Bibliographic Details

• Title: Tumor Metabolome Targeting and Drug Development
• Publisher: Springer
• Publication Date: 2014
• Language: English
• ISBN 10: 146149544X
• ISBN 13: 9781461495444
• Binding: Buch
• Condition: Neu
• Dimensions: 241W x 160H x 17D millimeters 241 millimeters width by 160 millimeters height by 17 millimeters depth
• Weight: 483 grams
• Seller catalogs:
  • Bücher

About this title

Synopsis

In this volume, the major metabolic alterations identified in cancer and tumor-associated cells are explored, including discussions of former and emerging approaches to drug development in targeting cancer cell metabolism.

The metabolic network in cells promotes the generation of both energy and biomass needed for them to grow, divide and differentiate. However, the metabolism of malignant cells generally varies from that of normal cells. These differences provide a platform for the discovery of new approaches to targeting potential vulnerabilities in cancer cells for therapeutic options Some of the significant changes that occur involve ATP production and consumption that modulates the ATP to ADP ratio, hypoxia and the effects of reactive oxygen species on glycolysis, regulation of mitochondrial respiration, induction and suppression of autophagy, and the Warburg effect and “reverse” Warburg effect--these topics and more are discussed in this volume.

About the Author

Dr. Steven B. Kanner is the Vice President of Discovery Biology at Astex Pharmaceuticals. He has been a pharmaceutical research leader with over 20 years of extensive experience in novel target identification and validation, assay development, both small molecule and antibody drug discovery, and expertise in oncology, immunology and inflammation. For more detail, please see the attached CV herewith.